These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27701365)

  • 1. In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.
    Med Lett Drugs Ther; 2016 Oct; 58(1505):e132. PubMed ID: 27701365
    [No Abstract]   [Full Text] [Related]  

  • 2. Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I.
    Kassel R; Sprietsma L; Rudnick DA
    J Pediatr Gastroenterol Nutr; 2015 Jan; 60(1):e5-7. PubMed ID: 23838819
    [No Abstract]   [Full Text] [Related]  

  • 3. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.
    Santra S; Baumann U
    Expert Opin Pharmacother; 2008 May; 9(7):1229-36. PubMed ID: 18422479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological and clinical profile of nitisinone (Orfadin(®) Capsules): a therapeutic agent for hereditary tyrosinemia type 1].
    Minoura H; Iwai M; Taniuchi Y; Katashima M; Takahashi H
    Nihon Yakurigaku Zasshi; 2015 Dec; 146(6):342-8. PubMed ID: 26657126
    [No Abstract]   [Full Text] [Related]  

  • 5. Nitisinone: new drug. Type 1 tyrosinemia: an effective drug.
    Prescrire Int; 2007 Apr; 16(88):56-8. PubMed ID: 17458044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting tyrosinaemia: a mathematical model of 4-hydroxyphenylpyruvate dioxygenase inhibition by nitisinone in rats.
    Ward JP; Dunster JL; Derks G; Mistry P; Salazar JD
    Math Med Biol; 2017 Sep; 34(3):335-390. PubMed ID: 27305933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.
    Larochelle J; Alvarez F; Bussières JF; Chevalier I; Dallaire L; Dubois J; Faucher F; Fenyves D; Goodyer P; Grenier A; Holme E; Laframboise R; Lambert M; Lindstedt S; Maranda B; Melançon S; Merouani A; Mitchell J; Parizeault G; Pelletier L; Phan V; Rinaldo P; Scott CR; Scriver C; Mitchell GA
    Mol Genet Metab; 2012 Sep; 107(1-2):49-54. PubMed ID: 22885033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of nitisinone in tyrosine pathway disorders.
    Lock E; Ranganath LR; Timmis O
    Curr Rheumatol Rep; 2014 Nov; 16(11):457. PubMed ID: 25266991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NTBC and alkaptonuria.
    Anikster Y; Nyhan WL; Gahl WA
    Am J Hum Genet; 1998 Sep; 63(3):920-1. PubMed ID: 9718357
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC).
    Pronicka E; Rowinska E; Bentkowski Z; Zawadzki J; Holme E; Lindstedt S
    J Inherit Metab Dis; 1996; 19(2):234-8. PubMed ID: 8739974
    [No Abstract]   [Full Text] [Related]  

  • 11. Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism.
    Hanauske-Abel HM; Popowicz A; Remotti H; Newfield RS; Levy J
    J Pediatr Gastroenterol Nutr; 2002 Jul; 35(1):73-8. PubMed ID: 12142814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confocal microscopy of corneal crystals in a patient with hereditary tyrosinemia type I, treated with NTBC.
    Schauwvlieghe PP; Jaeken J; Kestelyn P; Claerhout I
    Cornea; 2013 Jan; 32(1):91-4. PubMed ID: 22495034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study.
    Spiekerkoetter U; Couce ML; Das AM; de Laet C; Dionisi-Vici C; Lund AM; Schiff M; Spada M; Sparve E; Szamosi J; Vara R; Rudebeck M
    Lancet Diabetes Endocrinol; 2021 Jul; 9(7):427-435. PubMed ID: 34023005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evolution of a case of tyrosinemia type I treated with NTBC].
    Ros Viladoms J; Vilaseca Buscà MA; Lambruschini Ferri N; Mas Comas A; González Pascual E; Holme E
    An Esp Pediatr; 2001 Mar; 54(3):305-9. PubMed ID: 11262262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The fate of tyrosinaemic Hungarian patients before the NTBC aera.
    László A; Rózsa M; Sallay E; Tiszlavicz L; Janovszky A; Várkonyi A; Karg E; Wittmann G; Túri S; Ugarte M
    Ideggyogy Sz; 2013 Nov; 66(11-12):415-9. PubMed ID: 24555242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired cognitive functioning in patients with tyrosinemia type I receiving nitisinone.
    Bendadi F; de Koning TJ; Visser G; Prinsen HC; de Sain MG; Verhoeven-Duif N; Sinnema G; van Spronsen FJ; van Hasselt PM
    J Pediatr; 2014 Feb; 164(2):398-401. PubMed ID: 24238861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New drugs; nitisinone].
    Cohen AF; van Bronswijk H
    Ned Tijdschr Geneeskd; 2006 Nov; 150(46):2541-2. PubMed ID: 17152330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome.
    Couce ML; Dalmau J; del Toro M; Pintos-Morell G; Aldámiz-Echevarría L;
    Pediatr Int; 2011 Dec; 53(6):985-9. PubMed ID: 21752152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-Hydroxyphenylpyruvate dioxygenase as a drug discovery target.
    Yang DY
    Drug News Perspect; 2003 Oct; 16(8):493-6. PubMed ID: 14668946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nontransplant treatment of tyrosinemia.
    Holme E; Lindstedt S
    Clin Liver Dis; 2000 Nov; 4(4):805-14. PubMed ID: 11232358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.